NBI Insight - A valuable Research & Investment tool

 

NBI Insight is the leading Research & Investment publication within the Public Life Science Sector in the Nordic Region. 

 

 

It is a bi-weekly publication with 24 releases annually providing our clients with: 

 

  • Sector overview (fundamental and technical analysis) based on our proprietary developed NBI Nordic Life Science Index.

 

  • Share Price development for all public listed companies, as well as a broad range of proprietary sector analysis by Country, Stock Market, Market Cap and Business Segment. 

 

  • Pipeline news highlights for the entire sector which now includes more than 110 Companies.

 

  • Financials news in the sector. We track all capital fundings in the sector as well as new partnerships and acquisitions.

 

  • Through our proprietary IPO Index we continuously track the activity and performance of new Life Science companies entering the Nordic Stock Market. 

 

  • Comprehensive stock reports covering 3-5 individual companies in each issue.  

 

  • Two Investment recommendation Portfolios. We recommend buy candidates (both speculative and long term) as well as short-selling candidates and we keep track of our performance held up against the overall development in the Nordic Life Science Sector, the European EuroNext Biotech Index and the American Nasdaq Biotech Index. 

 

  • Overview of Nordic Bio Investors investment recommendations and share price targets for individual stocks. 

 

  • A detalied overview of the entire Nordic Life Science Sector by Company, Country, Stock Market, Market Cap (EUR), Business Segment and Medical Focus. 

 

 

 

 

 

Become a Client/Subscriber

 

For new Corporate Clients we are right now offering a free 6-week no commitment trial period which include 3 issues of NBI Insight.

 

For new Individual Clients we are offering a free 2-week no commitment trial period, which include 1 issue of NBI Insight. 

 

To sign up for a free trial period please fill in the requested information below:

Name        

Company 

E-mail      

Comments              

              

 

 

                                           Copyright NordicBioInvestor.com